Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513473 · ClinicalTrials.gov registry record · Phase 3
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT01513473 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 350 participants.
The verdict
NCT01513473, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.
Interventions
- DRUG insulin aspart
- DRUG insulin detemir
- DRUG insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2012-01-16 |
| Est. Completion | 2013-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01513473
The ClinicalTrials.gov registry entry for NCT01513473 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT01513473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01513473 about?
NCT01513473 is a clinical study titled "A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus". This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.
What is the current status of trial NCT01513473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2012-01-16. Estimated completion is 2013-07-30.
What interventions are being tested in trial NCT01513473?
The interventions under investigation include: insulin aspart (DRUG), insulin detemir (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT01513473?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.